DOCSNYSEThe short version
Doximity, Inc.
Doximity runs the dominant professional network for U.S. physicians and rents that audience to drug makers and hospitals — near-90% gross margins, about half of revenue in free cash flow, net cash and no debt.
From a September 2025 peak above $75, the shares fell close to 70% to about $18 by May 2026 after guidance cut fiscal-2027 growth to roughly 4%; they have since edged back to about $22.
$21.77
Share price
$4.0B
Market cap
$645M
Revenue, FY2026
85%
of U.S. physicians reached
SwipeScroll▾
The statements
Seven years of rising revenue and free cash flow, now decelerating
FY2020 → FY2026as reported · $
Revenue$645M+13%
Gross margin89.1%−1.1pp
Operating margin33.3%−6.6pp
Net income$196M−12%
EPS$0.98−12%
Free cash flow$326M+19%
As reported, FY2020–FY2026. Free cash flow computed as operating cash flow less capital expenditure.
- Revenue. Revenue climbed from $116M in FY2020 to $645M in FY2026, a compounding run that has now slowed to about 4% guided for FY2027 as pharmaceutical marketing budgets tightened.
- Margins and cash. Gross margin near 89% and roughly half of revenue converts to free cash flow — $326M reported in FY2026 — though GAAP operating margin slipped to 33% from 40% as AI spending stepped up.
- Balance sheet. No debt, $749M of net cash, and unbroken free-cash-flow growth every year since 2020 — the cash record is the steadiest thing in the story.
Founder control
80% of the votes on 31% of the economics — and an operating story the company concedes it can't fully verify
Economic stake vs voting power
Insiders hold 80.3% of the votes on 31.3% of the economics; the three index managers own about a quarter and cast under 6%. Super-voting Class B auto-converts to one-share-one-vote by June 2031.
- The governance gate. Doximity is controlled by an insider group holding 80.3% of the votes on 31.3% of the economics (the founder alone 76.3% on 28.9%),
- and in a February-March 2026 exchange with the SEC that same company conceded that the active-user engagement metrics its executives cite do not correlate highly with subscription revenue — and will be dropped from earnings calls — and that its systems cannot identify or allocate revenue by module.
- The counter. The SEC review closed with no enforcement, the super-voting structure auto-sunsets to one-share-one-vote in 2031, and the founder made zero open-market sales through the roughly 70% drawdown.
The AI contest
The upside leg of the value case is litigated, unbooked, and unverifiable at once
Where the AI-Search bet stands
| Leg | What it means |
|---|---|
| Litigated | OpenEvidence seeks an injunction barring Doximity's Pathway from its platform; claims survived a Jan 2026 motion to dismiss |
| Unbooked | No meaningful revenue before the FY2027 back half, against an asserted multibillion-dollar TAM |
| Unverifiable | Doximity told the SEC its systems cannot identify or allocate revenue by module |
The AI investment year lifted R&D to 20% of revenue and cut operating margin six points; the return is still a claim, not a line item.
- Litigated, unbooked, unverifiable. The AI-Search optionality that underpins Doximity's asymmetric margin-of-safety case is simultaneously litigated — OpenEvidence's amended complaint seeks a permanent injunction barring Doximity and its Pathway subsidiary from its platform, and the claims survived a January 22, 2026 motion to dismiss —
- unbooked, with management conceding no meaningful revenue before the fiscal 2027 back half against an asserted multibillion-dollar TAM, and unverifiable, because Doximity told the SEC its systems cannot identify or allocate revenue by module.
- No finding yet. No challenge has produced a finding against Doximity: the securities case settled with no admission and full insurance, the SEC letter closed with no enforcement, and Doximity is itself a counterclaimant in the suit.
The roughly $8 per share between the base (~$21) and bull (~$29) cases rests almost entirely on AI-Search monetization.
The business
A near-complete physician audience, rented to pharma and hospitals
>85%
of U.S. physicians are members
~3M
registered members
83%
of revenue from 125 customers
89%
gross margin
- The network is the asset. Membership is free; the paying customers are pharmaceutical manufacturers and health systems buying access to a verified, near-complete audience of prescribers.
- Three product families. Marketing Solutions is the core, alongside Hiring and free Workflow tools — telehealth, scheduling, and a clinical AI suite — that keep physicians engaged and feed the marketing data.
- Concentrated and subscription-based. Almost all revenue — $608M of $645M — is subscription, and the 125 customers spending over $500K each supply about 83% of it.
Moat and rivals
No rival for pharma marketing dollars matches Doximity on reach or profit
Doximity vs peers for pharma and health-system budgets
| Company (latest FY) | Rev. growth | Op. margin |
|---|---|---|
| Doximity (FY2026) | +13% | 33% |
| Phreesia (FY2026) | +14% | -1% |
| OptimizeRx (FY2025) | +19% | 11% |
| Definitive Healthcare (FY2025) | -4% | neg. |
Latest full-year filings. Definitive Healthcare's margin reflects large goodwill impairments; its operations run near breakeven. OptimizeRx has cut FY2026 guidance.
- The moat shows up as profit. Doximity earns a 33% operating margin and about $317M of free cash flow at a 49% margin, while the companies chasing the same budgets mostly operate at or below breakeven.
- The slowdown looks cyclical. Three unrelated peers softened at once and cited the same drug-pricing-policy shock, while Doximity's own engagement kept rising — the fingerprint of a demand pullback, not lost ground.
- The real test is AI-native. OpenEvidence, a clinical-answer tool now used by a majority of U.S. physicians, sells pharma ads the same way and raised capital at a reported $12B — roughly three times Doximity's market value.
The re-rating
Growth guided to ~4% from north of 20%, and retention roughly halved
Revenue growth, fiscal years
FY2027 is management's guidance. Net revenue retention fell from 157% in FY2022 to 109% in FY2026 as customer expansion roughly halved.
- A change in kind, not degree. After management guided FY2027 revenue to about 4% growth — down from north of 20% — the shares fell roughly 70% from their September 2025 peak.
- Retention tells the same story. Net revenue retention slid from 157% in FY2022 to 109% in FY2026; above 100% the base still expands, but the pace of that expansion has roughly halved.
- Management blames demand. It calls the market for digital pharma advertising soft, with policy uncertainty elevated, and expects it to grow at or below 5% this year — a cyclical account, not a platform problem.
Market trajectory
A $1 billion FY2028 target, now out of reach against a flat market
Revenue vs the 2023-era FY2028 target ($M)
Reaching $1B in FY2028 would need ~48% growth against a mid-single-digit market. The stated $18.5B addressable market has not changed since the 2021 IPO; Doximity sits at ~3.5% penetration.
- The digital shift already happened. Healthcare's move to digital advertising — the force behind early hypergrowth — reached about 72% of sector ad spend by 2026, up from 17% pre-pandemic; the easy conversion is largely spent.
- Market growth has stepped down three years running. The pharma HCP digital market cooled from pandemic-era 30-40% to management's mid-single-digit view, guided at or below 5% for FY2027.
- A maturing niche, not a rising tide. With a frozen TAM and ~3.5% penetration, the case reads as share gains in a flat pool; clinical AI is the one credible route to re-expanding it.
Cash quality
The reported cash is real — and unusually clean
1.67x
Operating cash flow / net income, FY2026
49%
Free-cash-flow margin
~0%
Capex as % of revenue
$749M
Net cash, no debt
- Profit turns into cash. Operating cash flow has exceeded net income every year since FY2023, and the classic forensic tests for manufactured earnings come back clean — days sales outstanding steady near 82.
- Capital-light by design. Capital spending is close to zero, so operating cash drops almost intact to free cash flow, which has grown every year since 2020 without going backward.
- Two caveats sit one layer in. Interest on the cash pile is about 14% of pretax profit and set to shrink, and FY2025's low tax rate flattered that year's earnings — the price-to-earnings comparison is noisier than it looks.
Owner earnings
Charge stock pay against cash flow and the growth mostly disappears
Reported vs post-SBC owner free cash flow ($M)
Owner FCF = reported free cash flow less stock-based compensation. SBC nearly doubled to $121.6M in FY2026, so reported FCF grew 19% while owner FCF grew about 2%.
- The multiple depends on the denominator. On reported free cash flow the stock trades near 10x enterprise value; on owner free cash flow after stock pay, closer to 16x — fair, not cheap, for ~4% growth.
- Buybacks run to stand still. Doximity repurchased $432M of stock in FY2026, yet diluted share count fell only about 1% as stock compensation refilled the pool.
- The margin of safety is in the balance sheet. Net cash and the buyback, not the headline multiple, are what cushion the downside.
Capital allocation
Buybacks are the only lever — well-built, unevenly timed
Share repurchases by fiscal year ($M)
About $921M repurchased since the 2021 IPO, all self-funded, no dividend. The completed $500M program averaged $43 a share into the 2025 peak; a new $500M program has about $493M left to deploy near $22.
- Bought the peak, then the trough. The largest program spent $500M at a $43 average just before the shares fell to about $22 — roughly twice the current price — though management has since reverted to buying near the lows.
- Dry powder against a depressed price. A fresh $493M authorization at today's price retires roughly twice the shares per dollar the prior program did; how fast it deploys will decide whether the record nets to accretive.
- No debt, no dividend, one small deal. The only acquisition is Pathway, an AI acqui-hire folded into the clinical-AI effort — not a growth-by-M&A strategy.
Two readings
Cyclical trough or structural ceiling — the same numbers, read two ways
The disagreement, on shared facts
| Shared fact | Cyclical (bull) | Structural (bear) |
|---|---|---|
| ~4% guided growth | Policy froze pharma budgets; spend returns | The digital shift is done; 4% is the new base |
| NRR at 109% | Moves with the budget cycle; rebounds | An 85%-penetrated base has little room left |
| AI Search launched | Billions in incremental TAM, back-half ramp | Unproven, unbooked, a direct AI-native rival |
The bull and bear work from identical disclosures. The disagreement lives almost entirely in whether the deceleration is temporary.
- Retention is mechanical. The company says net revenue retention moves with the growth rate — so a retention rebound and a demand rebound are the same event, not two independent confirmations.
- AI Search is a genuine adjacency. Management places it as incremental to today's budgets, not the existing pool re-labelled — but it is not yet a number in the revenue line.
- The early signals are the informative ones. SEC metric definitions, quarterly retention, and booked-revenue conversion arrive first and are harder to narrate around than slower, noisier signals.
Margin of safety
Priced for stagnation, floored by net cash and buybacks
Illustrative fair value per share
Bear: structural decline (~1%)
$15
Base: maturing niche (~4%)
$21
Bull: cyclical trough + AI (~8%)
$29
Gordon-growth valuations of ~$205M owner free cash flow plus $748.6M net cash over 183.1M shares; most sensitive to the discount rate.
- The price already reflects the guide. A reverse DCF implies roughly 0% perpetual growth on reported free cash flow, about 3.5% on owner free cash flow — the market is paying for the ~4% already guided, and no recovery beyond it.
- The distribution is asymmetric, toward protection. Net cash is about $4.09 a share, roughly 19% of the price, with no debt, and a $493M buyback authorization equals about 12% of the shares at today's price.
- The upside is optionality, not mispricing. Any AI-Search monetization is upside the price does not pay for — and, as the report shows, the least confirmable leg of the case.
What to watch
A debt-free cash compounder priced for stagnation — with the cyclical-versus-structural question still open.
- 01Net revenue retention: a turn back toward the mid-110s supports the cyclical read; holding at or below 109% supports the structural one.
- 02AI Search revenue: a disaggregated, material contribution in the fiscal 2027 back half, versus another year described as minimal.
- 03HCP digital-ad market growth: framed above high single digits, versus a second straight year at or below 5%.
- 04The OpenEvidence suit: resolution without an injunction touching Pathway or Ask, versus an adverse data-access ruling.
This distills a guided study built chapter by chapter — from the statements through the moat, the AI contest, founder control, and the margin of safety.
Compiled from the full report · 2026-07-12 · For information, not investment advice.